Efficacy and Safety of Rimegepant for Migraine Prevention in Children
Phase 3
640
about 11 years
6–17
52 sites in AR, CA, CO +19
About this study
Researchers are testing whether rimegepant, a medication, is effective and safe as a preventative treatment for migraine in children aged 6 to under 18 years. The trial will last approximately 3925 days and involve around 640 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Rimegepant
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
rimegepant
oral (Disintegrating Oral Tablet)
Primary: Change from baseline in the mean number of migraine days per month as measured over the 12-week double-blind phase of the study in adolescents with episodic migraine
Secondary: Change from baseline in the mean number of migraine days per month in the first 4 weeks (Weeks 1 through 4) of the double-blind treatment phase in adolescents with episodic migraine., Change from baseline in the mean number of migraine days per month over the entire course of the double-blind treatment phase in children and children and adolescents combined with episodic migraine., Change from baseline on the proportion of subjects that have at least a 50% reduction in the mean number of moderate to severe migraine days per month., Compare the use of acute migraine-specific medications (triptans) based on the change from baseline in monthly acute migraine specific medication days., Evaluate the frequency of hepatic-related adverse events in subjects treated with rimegepant., Evaluate the safety and tolerability of rimegepant as a preventative treatment for migraine in children and adolescents., The mean change from baseline in the Pediatric Quality of Life (PedsQL™) total score at Week 12 of the double-blind treatment phase in adolescents with episodic migraine.
Neurology